Clinical Trial Update: Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis [Phase 2]

View source ↗

Summary

Phase 2 trial assessing whether edaravone can mitigate radiation-induced temporal lobe necrosis in patients with nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Necrosis
• Nasopharyngeal Carcinoma

Drugs mentioned

• Edaravone (Edaravone)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Nasopharyngeal Carcinoma, Brain Necrosis | Phase 2 | Status: COMPLETED